Trial Profile
An Open-label, Randomized, Crossover Relative BA Study of Pharmacokinetics and Safety of New SDS-containing Tablet and Capsule Formulations of BILR 355 Compared to the Current Formulation (50 mg Tablet), After Single Dose Oral Administration of BILR 355 Plus Low Dose Ritonavir in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2014
Price :
$35
*
At a glance
- Drugs BILR 355 BS (Primary) ; BILR 355 BS (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 07 Oct 2014 New trial record